Company profile for Alkahest

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Alkahest is developing therapies derived from blood to treat neurological diseases, with an emphasis on age-related cognitive decline -- key medical challenges of our generation. The company’s breakthrough research has demonstrated that factors in blood plasma of young mice are able to reverse brain deficits in normal aging and Alzheimer’s disease models in mice. Clinical studies are being conducted in patients with diff...
Alkahest is developing therapies derived from blood to treat neurological diseases, with an emphasis on age-related cognitive decline -- key medical challenges of our generation. The company’s breakthrough research has demonstrated that factors in blood plasma of young mice are able to reverse brain deficits in normal aging and Alzheimer’s disease models in mice. Clinical studies are being conducted in patients with different types of dementia and other neurodegenerative diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
125 Shoreway Road, Suite D San Carlos, CA 94070
Telephone
Telephone
+1 (650) 801-0474
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2021/07/28/2270259/0/en/Alkahest-Strengthens-Management-Team-with-Addition-of-C%C3%A9sar-Cerezo-as-Chief-Medical-Officer.html

GLOBENEWSWIRE
28 Jul 2021

http://www.globenewswire.com/news-release/2021/03/08/2188969/0/en/Alkahest-to-Present-Positive-Data-from-Completed-Phase-2-Clinical-Trial-at-the-15th-International-Conference-on-Alzheimer-s-and-Parkinson-s-Disease.html

GLOBENEWSWIRE
08 Mar 2021

https://www.globenewswire.com/news-release/2021/01/28/2165766/0/en/Alkahest-Announces-Peer-Reviewed-Publication-Demonstrating-Safety-and-Tolerability-of-GRF6019-in-Patients-with-Mild-to-Moderate-Alzheimer-s-Disease.html

GLOBENEWSWIRE
28 Jan 2021

https://www.biospace.com/article/releases/grifols-to-acquire-alkahest-to-enhance-discovery-research-and-development-to-identify-innovative-therapies-for-age-related-diseases-based-upon-an-understanding-of-the-human-plasma-proteome/?s=79

BIOSPACE
07 Sep 2020

https://www.prnewswire.com/news-releases/grifols-to-acquire-alkahest-to-enhance-discovery-research-and-development-to-identify-innovative-therapies-for-age-related-diseases-based-upon-an-understanding-of-the-human-plasma-proteome-301124953.html

PRNEWSWIRE
06 Sep 2020
Alkahest Provides Corporate Update
Alkahest Provides Corporate Update

09 Jul 2020

// GLOBENEWSWIRE

https://www.globenewswire.com/news-release/2020/07/09/2059862/0/en/Alkahest-Provides-Corporate-Update.html

GLOBENEWSWIRE
09 Jul 2020

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty